CoChat
Sign Up
Cited by 81

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Matrix metalloproteinase-9 is up-regulated by CCL21/CCR7 interaction via extracellular signal-regulated kinase-1/2 signaling and is involved in CCL21-driven B-cell chronic lymphocytic leukemia cell invasion and migration.

Redondo-Muñoz, Javier, José Terol, María, García-Marco, José A., García-Pardo, Angeles·2008·Blood
DOI 10.1182/blood-2007-08-107300
Open this paper in CoChat — free account

Abstract

B-cell chronic lymphocytic leukemia (B-CLL) progression is frequently accompanied by clinical lymphadenopathy, and the CCL21 chemokine may play an important role in this process. Indeed, CCR7 (the CCL21 receptor), as well as matrix metalloproteinase-9 (MMP-9), are overexpressed in infiltrating B-CLL cells. We have studied whether MMP-9 is regulated by CCL21 and participates in CCL21-dependent migration. CCL21 significantly increased B-CLL MMP-9 production, measured by gelatin zymography. This was inhibited by blocking extracellular signal-regulated kinase-1/2 (ERK1/2) activity or by cell transfection with CCR7-siRNA. Accordingly, CCL21/CCR7 interaction activated the ERK1/2/c-Fos pathway and increased MMP-9 mRNA. CCL21-driven B-CLL cell migration through Matrigel or human umbilical vein endothelial cells (HUVEC) was blocked by anti-CCR7 antibodies, CCR7-siRNA transfection, or the ERK1/2 inhibitor U0126, as well as by anti-MMP-9 antibodies or tissue inhibitor of metalloproteinase 1 (TIMP-1). These results strongly suggest that MMP-9 is involved in B-CLL nodal infiltration and expand the roles of MMP-9 and CCR7 in B-CLL progression. Both molecules could thus constitute therapeutic targets for this disease.

Overview

Integrity signals

Registry

Crossref · 10.1182/blood-2007-08-107300

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 1 references

Research works printed but not linked: 18

  1. Zent, 2004, Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia., Curr Oncol Rep, 6, 348, 10.1007/s11912-004-0060-z · DOI
  2. Rai, 2007, Pathophysiologic mechanisms of chronic lymphocytic leukemia and their application to therapy., Exp Hematol, 35, 134, 10.1016/j.exphem.2007.01.021 · DOI
  3. Kakinuma, 2006, Chemokines, chemokine receptors, and cancer metastasis., J Leukoc Biol, 79, 639, 10.1189/jlb.1105633 · DOI
  4. Zlotnik, 2006, Chemokines and cancer., Int J Cancer, 119, 2026, 10.1002/ijc.22024 · DOI
  5. Till, 2002, The chemokine receptor CCR7 and α4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes., Blood, 99, 2977, 10.1182/blood.V99.8.2977 · DOI
  6. López-Giral, 2004, Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination., J Leukoc Biol, 76, 462, 10.1189/jlb.1203652 · DOI
  7. Deryugina, 2006, Matrix metalloproteinases and tumor metastasis., Cancer Metastasis Rev, 25, 9, 10.1007/s10555-006-7886-9 · DOI
  8. Stamenkovic, 2003, Extracellular matrix remodelling: the role of matrix metalloproteinases., J Pathol, 200, 448, 10.1002/path.1400 · DOI
  9. Bauvois, 2002, Production of matrix metalloproteinase-9 in early stage B-CLL: suppression by interferons., Leukemia, 16, 791, 10.1038/sj.leu.2402472 · DOI
  10. Kamiguti, 2004, The role of matrix metalloproteinase-9 in the pathogenesis of chronic lymphocytic leukemia., Br J Haematol, 125, 128, 10.1111/j.1365-2141.2004.04877.x · DOI
  11. Redondo-Muñoz, 2006, MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by α4β1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration., Blood, 108, 3143, 10.1182/blood-2006-03-007294 · DOI
  12. Murphy, 2002, Molecular interpretation of ERK signal duration by immediate early gene products., Nature Cell Biol, 4, 556, 10.1038/ncb822 · DOI
  13. Fridman, 2003, Cell surface association of matrix metalloproteinase-9 (gelatinase B)., Cancer Metastasis Rev, 22, 153, 10.1023/A:1023091214123 · DOI
  14. Gunn, 1998, A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes., Proc Natl Acad Sci U S A, 95, 258, 10.1073/pnas.95.1.258 · DOI
  15. Nagira, 1998, A lymphocyte-specific CC chemokine, seconary lymphoid tissue chemokine (SLC), is a highly efficient chemoattractant for B cells and activated T cells., Eur J Immunol, 28, 1516, 10.1002/(SICI)1521-4141(199805)28:05<1516::AID-IMMU1516>3.0.CO;2-J · DOI
  16. Okada, 2002, Chemokine requirements for B cell entry to lymph nodes and Peyer′s patches., J Exp Med, 196, 65, 10.1084/jem.20020201 · DOI
  17. Förster, 1999, CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs., Cell, 99, 23, 10.1016/S0092-8674(00)80059-8 · DOI
  18. Alfonso-Pérez, 2006, Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocytic leukemia., J Leuk Biol, 79, 1157, 10.1189/jlb.1105623 · DOI

Cited by

Metadata

Authors
Redondo-Muñoz, J., José Terol, M., García-Marco, J. A., & García-Pardo, A.
Affiliations
  • Departamento de Fisiopatología Celular y Molecular, Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas (CSIC), Madrid;
  • Servicio de Hematología y Medicina Oncológica, Hospital Clínico, Valencia; and
  • Servicio de Hematología, Hospital Puerta de Hierro, Madrid, Spain
Venue
Blood
Publisher
American Society of Hematology
Published
2008-01-01
Volume
111
Issue
1
Pages
383-386
ISSN
  • 0006-4971
  • 1528-0020
DOI
10.1182/blood-2007-08-107300
Cited by
81
References
1
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review